Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment Reporting Information [Line Items]
Total revenues	$ 25,453	$ 14,967	$ 43,485	$ 29,637
Cost of product revenue	4,318	1,699	8,536	4,240
Research and development	12,826	10,853	24,397	21,820
Selling, general and administrative	12,795	8,522	24,193	17,512
Total costs and operating expenses	29,939	21,074	57,126	43,572
Income (loss) from operations	(4,486)	(6,107)	(13,641)	(13,935)
Unallocated depreciation and amortization	(716)	(462)	(1,375)	(900)
Income (loss) before income taxes	(4,257)	(6,037)	(13,322)	(13,684)
Stock-based compensation	2,844	1,939	5,531	4,108
Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	21,585	7,506	35,815	18,379
Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	3,868	7,461	7,670	11,258
Product revenue
Segment Reporting Information [Line Items]
Total revenues	14,717	4,504	24,943	9,604
Product revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	14,717	4,504	24,943	9,604
Product revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	10,736	10,463	18,542	20,033
Research and development revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	6,868	3,002	10,872	8,775
Research and development revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	3,868	7,461	7,670	11,258
Operating segments
Segment Reporting Information [Line Items]
Total revenues	25,453	14,967	43,485	29,637
Cost of product revenue	4,318	1,699	8,536	4,240
Research and development	12,251	10,487	23,301	21,108
Selling, general and administrative	3,790	2,996	7,209	5,933
Total costs and operating expenses	20,359	15,182	39,046	31,281
Income (loss) from operations	5,094	(215)	4,439	(1,644)
Stock-based compensation	2,844	1,939	5,531	4,108
Operating segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	21,585	7,506	35,815	18,379
Cost of product revenue	4,318	1,699	8,536	4,240
Research and development	5,057	4,997	11,502	10,693
Selling, general and administrative	3,170	2,375	5,988	4,720
Total costs and operating expenses	12,545	9,071	26,026	19,653
Income (loss) from operations	9,040	(1,565)	9,789	(1,274)
Stock-based compensation	1,115	741	2,109	1,496
Operating segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	3,868	7,461	7,670	11,258
Cost of product revenue	0	0	0	0
Research and development	7,194	5,490	11,799	10,415
Selling, general and administrative	620	621	1,221	1,213
Total costs and operating expenses	7,814	6,111	13,020	11,628
Income (loss) from operations	(3,946)	1,350	(5,350)	(370)
Stock-based compensation	257	252	495	494
Operating segments | Product revenue
Segment Reporting Information [Line Items]
Total revenues	14,717	4,504	24,943	9,604
Operating segments | Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	10,736	10,463	18,542	20,033
Corporate, non-segment
Segment Reporting Information [Line Items]
Total costs and operating expenses	(8,610)	(5,316)	(16,335)	(11,042)
Unallocated depreciation and amortization	(741)	(506)	(1,426)	(998)
Income (loss) before income taxes	(4,257)	(6,037)	(13,322)	(13,684)
Stock-based compensation	$ 1,472	$ 946	$ 2,927	$ 2,118